| Size | Price | Stock | Qty |
|---|---|---|---|
| 10g |
|
||
| Other Sizes |
|
Purity: ≥98%
Ceftazidime (GR-20263; GR20263; LY-139381; Tazidime; Fortaz, Tazicef; Avycaz) is a potent, third generation, and broad-spectrum β-lactam antibiotic approved for use as an antimicrobial agent for treating febrile neutropenia in patients with cancer. It is administered intravenously or intramuscularly. As a class, cephalosporins have activity against Gram-positive and Gram-negative bacteria. The balance of activity tips toward Gram-positive organisms for earlier generations; later generations of cephalosporins have more Gram-negative coverage. Ceftazidime is one of the few in this class with activity against Pseudomonas.
| Targets |
β-lactam
|
|---|---|
| ln Vitro |
Against strains of P. aeruginosa, ceftazidime (0–8 μg/mL, approximately, 24 h) exhibits antibacterial and anti-biofilm properties[2].
Ceftazidime exhibits inhibitory effects on isolates of S. maltophilia at concentrations of 0–40 μg/mL, roughly 18–20 hours[3]. |
| ln Vivo |
In a murine thigh infection model, ceftazidime (2 h infusion of injection, 2 000 mg every 8 h for 24 h) moderately reduces bacterial density[4].
|
| Cell Assay |
Cell Line: P. aeruginosa strains (PAO1, PA1, PA2)
Concentration: 0-8 µg/mL approximately Incubation Time: 24 h Result: showed MIC values of 2-4 µg/mL for antibacterial and anti-biofilm activities. |
| Animal Protocol |
Animal Model: Murine thigh infection model[4]
Dosage: 2000 mg Administration: 2 h infusion of injection, every 8 h for 24 h. Result: decreased bacterial density when compared to the isogenic strain of NDM (New Delhi metallo-β-lactamase). |
| References |
|
| Molecular Formula |
C22H22N6O7S2
|
|---|---|
| Molecular Weight |
546.5761
|
| Elemental Analysis |
C, 48.34; H, 4.06; N, 15.38; O, 20.49; S, 11.73
|
| CAS # |
72558-82-8
|
| Related CAS # |
Ceftazidime pentahydrate;78439-06-2
|
| Appearance |
C, 48.34; H, 4.06; N, 15.38; O, 20.49; S, 11.73
|
| SMILES |
CC(C)(C(=O)O)ON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C[N+]4=CC=CC=C4)C(=O)[O-]
|
| InChi Key |
ORFOPKXBNMVMKC-LGJNPRDNSA-N
|
| InChi Code |
InChI=1S/C22H22N6O7S2/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34)/b26-13+
|
| Chemical Name |
(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
|
| Synonyms |
Fortaz; Fortum; GR 20263; GR-20263; GR20263; LY 139381; LY-139381; LY139381; Tazidime; Ceftazidime anhydrous; Ceftazidime Pentahydrate;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : 25 ~100 mg/mL (~182.96 mM)
DMSO : ~2 mg/mL ( ~3.65 mM ) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.81 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.81 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.81 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 10% DMSO+40% PEG300+5% Tween-80+45% Saline: ≥ 2.08 mg/mL (3.81 mM) Solubility in Formulation 5: 100 mg/mL (182.96 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8296 mL | 9.1478 mL | 18.2956 mL | |
| 5 mM | 0.3659 mL | 1.8296 mL | 3.6591 mL | |
| 10 mM | 0.1830 mL | 0.9148 mL | 1.8296 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
